Although preliminary evidence suggests 's efficacy in symptom control for anxiety and depression-psychiatric disorders that significantly impact mental health-much remains to be understood about its effects on the central nervous system (CNS) and how to optimize treatment for these disorders. This study aims to conduct a narrative review to evaluate pharmaceutical care in treating symptoms of anxiety and depression alongside use, focusing on safety and therapeutic efficacy optimization. We seek to conceptualize anxiety and depression disorders, review evidence on use, evaluate the evidence quality, and identify knowledge gaps. Twelve articles were identified, revealing a significant gap in the literature regarding the integration of pharmaceutical care with -based therapies, specifically for anxiety and depression. Despite a growing interest in the relationship between and mental health, current research is insufficient for a comprehensive understanding. The relationship between use and anxiety and depression disorders requires further, more targeted investigations. This study underscores the importance of future research to fill existing gaps, providing informed insights and robust guidelines for the safe and effective use of as part of the treatment for anxiety and depression. It is crucial that pharmaceutical care integrates these therapies responsibly to improve the overall well-being of patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270281PMC
http://dx.doi.org/10.3390/pharmacy12040100DOI Listing

Publication Analysis

Top Keywords

anxiety depression
20
pharmaceutical care
16
mental health
8
depression disorders
8
anxiety
6
depression
5
exploring significance
4
pharmaceutical
4
significance pharmaceutical
4
care
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!